TCL.AU

12.62

-0.55%↓

BXB.AU

18.52

+1.87%↑

COL.AU

17.55

+0.17%↑

SVW.AU

41.39

-0.91%↓

QAN.AU

8.17

+1.87%↑

TCL.AU

12.62

-0.55%↓

BXB.AU

18.52

+1.87%↑

COL.AU

17.55

+0.17%↑

SVW.AU

41.39

-0.91%↓

QAN.AU

8.17

+1.87%↑

TCL.AU

12.62

-0.55%↓

BXB.AU

18.52

+1.87%↑

COL.AU

17.55

+0.17%↑

SVW.AU

41.39

-0.91%↓

QAN.AU

8.17

+1.87%↑

TCL.AU

12.62

-0.55%↓

BXB.AU

18.52

+1.87%↑

COL.AU

17.55

+0.17%↑

SVW.AU

41.39

-0.91%↓

QAN.AU

8.17

+1.87%↑

TCL.AU

12.62

-0.55%↓

BXB.AU

18.52

+1.87%↑

COL.AU

17.55

+0.17%↑

SVW.AU

41.39

-0.91%↓

QAN.AU

8.17

+1.87%↑

Inicio・Lista de Acciones・CSL Ltd

CSL Ltd

Cerrado

Sector

282.12 -1.62

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

281.82

Máximo

282.21

Métricas clave
By Trading Economics
Ingresos	1.9B
Ventas	8.1B
BPA	4.159
Margen de beneficio	23.606

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+15.43 upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-2.6B 136B
Apertura anterior	283.74
Cierre anterior	282.12

Noticias sobre sentimiento de mercado

By Acuity

43%

57%

199 / 472 Clasificación en Industrials

CSL Ltd Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

12 ago 2024, 23:23 UTC

Ganancias

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12 ago 2024, 22:49 UTC

Ganancias

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

12 feb 2024, 22:16 UTC

Ganancias

CSL Says 1st Half Profit Rises, Boosts Dividend -- Update

12 feb 2024, 22:00 UTC

Ganancias

CSL Says 1st Half Profit Rises, Boosts Dividend

22 oct 2024, 22:53 UTC

Charlas de Mercado

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10 oct 2024, 22:20 UTC

Charlas de Mercado

CSL Bull Looking for Update on Gross Margin -- Market Talk

13 ago 2024, 00:33 UTC

Charlas de Mercado

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12 ago 2024, 22:34 UTC

Ganancias

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12 ago 2024, 22:18 UTC

Ganancias

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12 ago 2024, 22:18 UTC

Ganancias

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12 ago 2024, 22:17 UTC

Ganancias

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12 ago 2024, 22:16 UTC

Ganancias

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12 ago 2024, 22:15 UTC

Ganancias

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12 ago 2024, 22:14 UTC

Ganancias

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12 ago 2024, 22:13 UTC

Ganancias

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12 ago 2024, 22:13 UTC

Ganancias

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12 ago 2024, 22:11 UTC

Ganancias

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12 ago 2024, 22:10 UTC

Ganancias

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12 ago 2024, 22:09 UTC

Ganancias

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12 ago 2024, 22:08 UTC

Ganancias

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12 ago 2024, 22:07 UTC

Ganancias

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

12 ago 2024, 22:07 UTC

Ganancias

CSL Final Dividend US$1.45/Share

13 feb 2024, 01:50 UTC

Charlas de Mercado

Ganancias

CSL Still Confident on Long-Term Value at Vifor Business -- Market Talk

13 feb 2024, 00:39 UTC

Charlas de Mercado

Ganancias

UBS Sees Mixed Bag in CSL's Half-Year Results -- Market Talk

12 feb 2024, 22:01 UTC

Ganancias

CSL Says 1H Profit Rises, Boosts Dividend -- Update

12 feb 2024, 21:45 UTC

Principales Noticias

Ganancias

CSL Says 1H Profit Rises, Boosts Dividend

12 feb 2024, 21:35 UTC

Ganancias

CSL Says 1H Result Driven by CSL Behring Unit, Especially Immunoglobulins

12 feb 2024, 21:33 UTC

Ganancias

CSL Anticipates Loss in 2H for Flu-Vaccine Unit Seqirus Due to Seasonality of Business

12 feb 2024, 21:33 UTC

Ganancias

CSL Says FY 2024 Underlying Profit Growth Expected 13%-17% on-Year

12 feb 2024, 21:32 UTC

Ganancias

CSL Says Underlying Profit Expected in Range of US$2.9-US$3.0 Bln at Constant Currency

Comparación entre iguales

Cambio de precio

CSL Ltd Esperado

Precio Objetivo

By TipRanks

15.43% repunte

Estimación a 12 meses

Media 325.069 AUD 15.43%

Máximo 348.5 AUD

Mínimo 278 AUD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CSL Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para CSL Ltd Dist en los últimos 3 meses.

Sentimiento

By Acuity

199 / 472 Clasificación en

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de CSL Ltd

CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.